• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Reprieve Cardiovascular touts early ADHF therapy study data

Reprieve Cardiovascular touts early ADHF therapy study data

December 20, 2018 By Fink Densford

Reprieve Cardiovascular

Reprieve Cardiovascular this week released early study results from the Target II study of its Reprieve-Guided Diuretic Therapy intended to improve fluid management for patients with acute decompensated heart failure, touting improvements in fluid management optimization.

Early data from the study were presented by study investigator Dr. Piotr Ponikowski of Wroclaw Medical University at the Heart Failure Congress this month, the Milford, Mass.-based company said.

“These results change the way we need to think about diuretic therapy. The new results of this study are encouraging as they show we were able to safely increase the rate of fluid loss in decompensated heart failure patients using Reprieve-Guided Diuretic Therapy,” Ponikowski said in a prepared statement.

Investigators in the study explored the use of Reprieve’s therapy to optimize fluid management for ADHF patients, looking to provide a safe net volume reduction and alleviate related symptoms, Reprieve Cardio said.

Results from the trial, which was based off the previously completed Target 1 feasibility trial, indicated that treatment with the therapy resulted in a net fluid loss off 3661 ml over 24 hours, significantly more than the 1754 ml reported in the control group from the Target 1 trial.

Reprieve Cardiovascular said it will release other details from the trial in the future.

“We are thrilled to reveal additional data that demonstrates a promising step towards a new therapy for patients suffering from Acute Decompensated Heart Failure. Reprieve Cardiovascular’s fluid management technology may precisely enable the controlled decongestive therapy that ADHF patients need. Our Guided Diuretic Therapy has the potential to establish a new frontline standard of care for heart failure patients, allowing physicians to maximize fluid removal while protecting patients from the potential negative impact of excessive fluid loss. At D-HF we continued to see overwhelming interest in our initial study and technology, similar to the interest we experienced at the Heart Failure Society of America meeting in September and ESC – Heart Failure 2018 in May,” CEO Jim Dillon said in a press release.

In September, RenalGuard Solutions said that it closed a $7 million financing round joined by Abiomed (NSDQ:ABMD) to support its newly formed affiliate company, Reprieve Cardiovascular.

Filed Under: Cardiovascular, Clinical Trials Tagged With: reprievecardiovascular

More recent news

  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
  • Former Masimo COO is joining BD to run Connected Care

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy